Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes Mellitus

被引：196
|
作者：
Chen, W. -W. [1 ]
Li, L. [2 ,3 ]
Yang, G. -Y. [1 ]
Li, K. [1 ]
Qi, X. -Y. [1 ]
Zhu, W. [1 ]
Tang, Y. [4 ]
Liu, H. [5 ]
Boden, G. [6 ,7 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 2, Dept Endocrinol, Chongqing 400010, Peoples R China
[2] Chongqing Med Univ, Minist Educ, Dept Clin Biochem, Chongqing, Peoples R China
[3] Chongqing Med Univ, Minist Educ, Key Lab Lab Med Diagnost, Chongqing, Peoples R China
[4] Centocor Inc, Oncol Res, Malvern, PA 19355 USA
[5] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA
[6] Temple Univ, Sch Med, Div Endocrinol Diabet Metab, Philadelphia, PA 19122 USA
[7] Temple Univ, Sch Med, Clin Res Ctr, Philadelphia, PA 19122 USA
来源：
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2008年 / 116卷 / 01期
关键词：
FGF-21; insulin resistance; T2DM;
D O I：
10.1055/s-2007-985148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Fibroplast growth factor (FGF-21) is a recently discovered metabolic regulator. Its pathophysiologic role in humans remains unknown. In this study, we have investigated whether or not plasma FGF-21 level was different in patients with type 2 diabetes mellitus (T2DM) and nondiabetic controls. We also assessed associations between plasma FGF-21 body composition and several metabolic parameters. Fasting FGF-21 levels were significantly increased in patients with T2DM compared with controls (1.82 +/- 0.65 vs. 1.53 +/- 0.60 mu g/L, P<0.05). In T2DM patients, fasting plasma FGF-21 correlate negatively with fasting blood glucose (r = -0.31, P< 0.05). Multiple regression analysis showed that FBG, plasma insulin and HOMA(IS) were independent influencing plasma FGF-21 levels. The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM.
引用
收藏
页码：65 / 68
页数：4
相关论文
共 50 条
  • [31] Elevated plasma levels of SPARC in patients with newly diagnosed type 2 diabetes mellitus
    Wu, Dandong
    Li, Ling
    Yang, Mengliu
    Liu, Hua
    Yang, Gangyi
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 165 (04) : 597 - 601
  • [32] SERUM VISFATIN LEVELS IN PATIENTS WITH SUBCLINICAL AND NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS
    Celebi, Aslan
    Gurler, Mujgan
    Koc, Deniz Ogutmen
    Ozdemir, Ali Abbas
    Ekizoglu, Ismail
    Altay, Murat
    Degirmencioglu, Serife
    ACTA MEDICA MEDITERRANEA, 2017, 33 (02): : 197 - 201
  • [33] Increase in Serum Fibroblast Growth Factor-21 (FGF-21) Predicts Development of Diabetes in IGT Subjects and Pioglitazone Attenuates the Increase in FGF-21 and Reduces Conversion of IGT to T2DM
    Alonzo, Ryan
    Chavez-Velazquez, Alberto
    Martinez, Robert
    Velez-Garza, Jorge
    Carreon, Marco
    Musi, Nicolas
    Defronzo, Ralph A.
    Tripathy, Devjit
    DIABETES, 2016, 65 : A482 - A482
  • [34] VITAMIN D LEVELS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
    Uzkeser, H.
    Yildirim, K.
    Bilen, H.
    Karatay, S.
    Akbas, M.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S591 - S591
  • [35] Fibroblast Growth Factor-21 (FGF-21) as a Novel Marker of Metabolic Complications in Type 2 Diabetes and Obesity
    Matuszek, Beata
    Lenart-Lipinska, Monika
    Duma, Dariusz
    Solski, Janusz
    Nowakowski, Andrzej
    DIABETES, 2010, 59 : A562 - A562
  • [36] Sustained Release of FGF-21 from a Genetically Engineered Injectable Depot for the Treatment of Type 2 Diabetes
    Gilroy, Caslin A.
    Chilkoti, Ashutosh
    DIABETES, 2017, 66 : A289 - A289
  • [37] The effect of 12 weeks of training in water on serum levels of SIRT1 and FGF-21, glycemic index, and lipid profile in patients with type 2 diabetes
    Bahram Jamali Gharakhanlou
    Solmaz Babaei Bonab
    International Journal of Diabetes in Developing Countries, 2022, 42 : 727 - 734
  • [38] The effect of 12 weeks of training in water on serum levels of SIRT1 and FGF-21, glycemic index, and lipid profile in patients with type 2 diabetes
    Gharakhanlou, Bahram Jamali
    Bonab, Solmaz Babaei
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2022, 42 (04) : 727 - 734
  • [39] Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus
    Hu, Y.
    Liu, J.
    Zhang, H.
    Xu, Y.
    Hong, T.
    Wang, G.
    DIABETES & METABOLISM, 2016, 42 (05) : 358 - 363
  • [40] INCREASED UROCORTIN-2 LEVELS ARE ASSOCIATED WITH INSULIN RESISTANCE IN SUBJECTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS
    Guler, A.
    Calan, M.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2021, 17 (03)
12345